ARCH Venture Partners and Mubadala Capital led a $72m Series A funding round in Pretzel Therapeutics.

ARCH Venture Partners, a venture capital firm, and Mubadala Capital, a global ventures platform, led a $72m Series A funding round in Pretzel Therapeutics, a biotechnology company harnessing the intricacies of mitochondrial biology to develop groundbreaking therapies, with participation from HealthCap, Cambridge Innovation Capital, Cambridge Enterprise, Angelini Ventures, GV, Invus, Eir Ventures, GU Ventures, and Karolinska Institutet Holding. “We are excited to pioneer a new era in the treatment of diseases related to mitochondrial dysfunction. The expertise we have assembled and the platform technologies we have created will allow new inroads into treating both rare genetic diseases as well as common diseases of aging. We’re proud to be backed by an outstanding investor syndicate, with a Series A financing that will allow us to prosecute preclinical development across our pipeline and continue to build out our talented team,” Jay Parrish, Pretzel Chairman of the Board and Chief Executive Officer.